More results concerning Liz Parrish, this is the important part:
No negative effects have been reported, and there are no visible detrimental effects in blood analysis thus far; providing tentative evidence of safety in the first human test of BioViva’s dual gene therapy strategy.
Biomarker analysis and MRI imaging data from the past year have revealed beneficial metabolic changes and muscle improvement in Elizabeth Parrish, CEO of BioViva USA Inc. and recipient of BioViva’s experimental dual gene therapy in September 2015.
Read more
Given the testing in mice, I would have volunteered to be patient zero, but didn’t have the money. The big news won’t be the beneficial effects of this dual gene therapy, but a radical decrease in cost.